Conclusions: Transradial CTO PCI can be performed with similar success and complication rates with transfemoral CTO PCI, but is associated with longer procedural and fluoroscopy times.

TCT-196

Meta-Analysis on the impact of percutaneous coronary intervention of Chronic Total Occlusions on Long-term Mortality

Joëlle Elias¹, Loes Hoebers¹, Bimmer Claessen¹, Jose P. Henriques¹

¹Academic Medical Center - University of Amsterdam, Amsterdam, Netherlands Background: Patients with coronary artery disease with a chronic total occlusion (CTO)

are associated with worse clinical outcome compared to patients without a CTO. Percutaneous coronary intervention (PCI) of CTOs may have a beneficial effect on survival. In literature mainly small, observational and predominantly single center studies exist about successful PCI and the impact on reducing long-term mortality for CTO. **Methods:** This meta-analysis compared the long-term mortality of successful versus

failed PCI for CTO. Relevant studies were examined and analyzed independently by two investigators. To prevent distortion of the results by the inclusion of (sub-)acute 100% occlusions, a subgroup analysis was performed on only those studies which included patients with a CTO of at least 3 months.

Results: We identified 27 studies eligible for inclusion in this meta-analysis, including 11,085 CTO patients with successful and 4,347 CTO patients with unsuccessful revascularization (mean follow-up duration 1 to 10 years). We did not find any randomized controlled trials between CTO PCI versus medical treatment only. Successful CTO PCI was associated with reduced mortality in comparison to failed CTO PCI (odds ratio (OR): 0.52, 95%CI: 0.43-0.62,p-value= 0.01). For the subgroup analyses the results remained qualitatively similar (OR: 0.47, 95%CI: 0.35-0.64, p-value < 0.01) (figure 1). **Conclusions:** This meta-analysis confirmed previous findings of a reduced mortality after successful versus failed CTO PCI. Randomized controlled trials are needed to confirm the value of PCI in patients with a CTO in reducing the mortality.

Figure 1. Meta-analyses of studies evaluating successful versus failed CTO revascularization on long-term mortality.

1A. All included studies.

	Ballin	alut.	1.66	÷	6 - C	URBAS RUNNING	Date Rate		
Thely of Subprove	110000	104	Powerine.	1004	Fengr	B-4 Received, 1979 (1	#1.0, Parellott, 555 11		
Argin		41		1.28	0.78	218,8552,188	and the second s		
Avelation	110	111	- 1t	3118	1.17%	3473311.015			
A/0		111	- t)	188	1.3%	431-012.476			
Sorgia	- 14	137		- 44	145	834(0.21, 1.26)			
Chart.	·	1.72		- 24	1.116	43804.536	And a second sec		
die 1. alienume	- X	1.15		- 411	116	111022-030			
Constant		200		- 1ati	114	4743-13.220			
Faint		140	1.1	1.04	1.6%	1703415.12	table and the second		
-bus	29	247	1.18	704	100	100000.004			
in house	1.1	0.7		1100	11%	215,0106,108			
Appropriate line	18	347	10.3	1.39	1.0%	1428311138	and the second sec		
10h Ameri	21	22.8	1.18	1100	104	012/01/01 10:00			
iomara .	28			154	11.15	0.77 8 13 1.16			
		364		60	1.0%	01001010.178			
And Law	- 14	1228	1.44	AND	110	0.407.0149.0100			
No. 10		110	1.40	· 127	1.7%	8,19,0116,0.001			
the same for	- 2	110		1.44	1.94	010010-010			
librari .	A	184	1.1.1	- 41	118	0.38-0-10, 1.4.5	and the second sec		
Process of	120		110	ing in the second	1.7%	479206172			
iona -				1.0	1.1%	0 10-01-08, 1 Mg			
hugens	100	1441	1.00	44.4	10.0%	0473-14.048			
Tanana	23	310		6.1	100	0.003027.245			
talentill.	1.1	144	11	140	4.1%	8.1010.18.5.75			
wind for		100		1.6		And writers going			
1 programming in	42	1111	- 18	100	128	871.0.47.1.010			
Carlin .	- 3	87	12	1.00	1.0%	336512.000	and a second sec		
9.9	1.24	1.052	19	1.00	1,7%	0.00.00.000			
hand play of		*****		4141	interna	4510.41.542			
hour wants	1000			100	1.1.1		Contraction of the second		
Inducements Tauf	440.000	- 41 m	10.15		-	-			
	A		1.1.1				「油酸」、(約~二年)、一種、三種		

18. Subgroup of studies with CTO definition of at least 3 months.

	lactorial.		Failed		Charles Russia		Game Hades	
Note or Subgroup.	Tradic	THE	X-tests.	714	Degle	H.H. Review, Hilly Cl.	Mid. Residen, 875.CI	
10		. 679	1.14	105	174	0-21.2013, 8740		
inger (18	127			17.7%	2143023.036		
Rak	1.2	133		20	2.8%	2.04(8.21, 8.16)		
er (and other	1.12	1.891			1,178	171831.0.00		
1000	14	. 1643	. 64	364	11.76	411811.439		
**	4	200		82	4.4%	104/074 213	A CONTRACTOR OF A CONTRACTOR OF A CONTRACTOR OF A CONTRACTOR A CONTRAC	
Netvise:	34	1224			12/18.	1 10 12 44, 5 100	-	
ACCENT OF A		1156	1.10	- 111	1.7%	10103-0.005		
regentili (1.194	1.18	40	10	1 83436-0,473		
VALAC	228	104	100	348	133%	12.78.00.468, 5.922	-	
and a loss	. 25	124		11	5.00	10103-0140		
uterd.	47	344	0.01	140	6.7%	0.0434.04.475	(marked)	
11	128	1002	14	196	11.4%	10103130	1.00	
WAR JOIN CO		inter.		31.75	100.04	8.47 (8.7), 0.84	•	
faller president	184		200					
Intelligences (Tory)	114.00	P+ 30.7 F - 2.5	1. Br C	19-11	100,71	578	10 V)	

TCT-197

Long-term Survival Benefit of Revascularization compared with Medical Therapy in Patients with Coronary Chronic Total Occlusion and Well-developed Collateral Circulation

Woo Jin Jang¹, Young Bin Song², Joo-Yong Hahn³

¹Cardiac and Vascular Center, Samsung Medical Center, Gangnam-gu, Seoul, ²Samsung Medical Center, Seoul, Korea, Republic of, ³Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of

Background: Little is known about the clinical outcomes and optimal treatment strategies of chronic total occlusion (CTO) with well-developed collateral circulation. **Methods:** We screened 2,024 consecutive patients with at least one CTO detected on coronary angiogram. Of these, we analyzed data from 738 patients with Rentrop 3 grade collateral circulation who were treated with medical therapy alone (n=236), coronary artery bypass grafting (n=170) or percutaneous coronary intervention (PCI) (n=332; 80.1% successful). Patients who underwent revascularization and medical therapy (revascularization group, n =502) were compared to those who underwent medical therapy alone (medication group, n=236) in terms of cardiac death and major adverse cardiac events (MACE), defined as the composite of cardiac death, myocardial infarction, or repeat revascularization.

Results: During a median follow-up duration of 42 months, multivariate analysis revealed a significantly lower incidence of cardiac death (hazard ratio [HR] 0.29; 95% confidence interval [CI] 0.15 to 0.58; p < 0.01) and MACE (HR 0.32; 95% CI 0.21 to 0.49; p < 0.01) in the revascularization group compared to the medication group. After propensity score matching, the incidence of cardiac death (HR 0.27; 95% CI 0.09 to 0.80; p=0.02) and MACE (HR 0.44; 95% CI 0.23 to 0.82; p=0.01) were still significantly lower in the revascularization group than in the medication group.

Table. Clinical outcomes in all study patients

	Medication	Revascularization	Unadjusted HR (95% CI)	p Value	³ Adjusted HR(95% Cl)	p Value				
Total population (n=738)	n=236	n=502								
All-cause death	44 (18.6)	39 (7.8)	0.39 (0.26-0.61)	<0.01	0.44 (0.27-0.71)	<0.01				
Cardiac death	23 (9.7)	17 (3.4)	0.33 (0.18-0.61)	<0.01	0.29 (0.15-0.58)	<0.01				
мі	2 (0.8)	4 (0.8)	0.91 (0.17-4.98)	0.92	1.04 (0.16-6.80)	0.97				
¹ Repeat revascularization	37 (15.7)	34 (6.8)	0.38 (0.24-0.61)	<0.01	0.38 (0.23-0.63)	<0.01				
² MACE	59 (25.0)	51 (10.2)	0.36 (0.25-0.52)	<0.01	0.32 (0.21-0.49)	<0.01				
Data are presented as n (%).										

¹Repeat revascularization included target vessel revascularization-PCI, non-target vessel revascularization-PCI and coronary artery bypass grafting (CABG).

 $^2\text{Major}$ adverse cardiac events (MACE) included cardiac death, MI, and repeat revascularization with PCI or CABG.

³Adjusted covariates include age, ACS, CTO of LAD, multiple CTOs, previous PCI and Proximal to mid CTO

 $\label{eq:ACS} ACS = acute \mbox{ coronary syndrome; } CI = \mbox{ confidence interval; } CTO = \mbox{ coronary chronic total occlusion; } HR = \mbox{ hazard ratio; } LAD = \mbox{ left anterior descending artery; } MI = \mbox{ myocardial infarction; } PCI = \mbox{ percutaneous coronary intervention } \end{cases}$

Conclusions: In patients with coronary CTO and well-developed collateral circulation, aggressive revascularization may reduce the risk of cardiac mortality and MACE. These findings need to be confirmed in randomized controlled trials.

TCT-198

Retrograde Recanalization Of Chronic Total Occlusions In Europe: Procedural And In-Hospital Outcomes From The Multicenter ERCTO Registry

Alfredo R. Galassi¹, Georgios Sianos², Gerald S. Werner³, Javier Escaned⁴, Francesco Marzà⁵, Marouane Boukhris⁶, Salvatore D. Tomasello⁶, Carlo Di Mario⁷ ¹University of Catania, Catania, Italy, ²Aristotle University, Thessaloniki, Macedornia, ³Klinikum Darmstadt, Darmstadt, Germany, ⁴Hospital Clinico San Carlos, Madrid, Spain, ⁵Ferrarotto Hospital, Catania, Catania, ⁶Cannizzaro Hospital, Catania, Catania, ⁷Imperial College London, London, United Kingdom

Background: The aim of this study was to describe the five-year European experience of retrograde percutaneous coronary interventions (PCI) revascularization for complex chronic total occlusions (CTOs) of coronary arteries.

Methods: Demographic data, procedural outcomes and in-hospital clinical events were collected on 1582 consecutive lesions of 1395 patients enrolled between January 2008 and December 2012 having retrograde CTO PCI at 44 European medical centers by 45 experienced interventionalist operators. A retrograde J-CTO score was used to better describe success according to lesion difficulty. Data about clinical follow-up were collected.

Results: Patients mean age was 62.0 ± 10.4 years. During the procedure the retrograde approach was used as first line strategy in 76.2% of cases, while immediately after antegrade failed approach in 23.8% of cases. Procedural success was achieved in 75.3% of cases. A major complication occurred in 16 patients (1.0%). In multi-variable analysis, age of the patient (per 10-year increase) (OR:1.19, 95%CI:1.03-1.34; p=0.02), lower operator volume (OR:3.00, 95%CI:2.41-4.21; p< 0.001) and increased retrograde J-CTO score (OR:0.42, 95%CI:0.24-0.74; p< 0.001) were recognized as independent predictors of procedural failure. The mean follow-up period was 24.7 ± 15.0 months. Major adverse cardiac and cerebral events (MACCE) occurred in 13.6% of cases (cardiac death 1.9%, myocardial infarction 3.2%, stroke 0.6% and target vessel revascularization 13%). By multivariate Cox regression, the independent predictors of MACCE were: male gender (HR:0.47, 95% CI:0.30-0.74; p=0.01); prior myocardial infarction (HR:1.45, 95%CI:1.01-2.09; p=0.04); number of previous attempts (HR:1.63, 95%CI:1.36-1.95; p< 0.001); CTO length (HR:1.01, 95%CI:1.00-1.02; p=0.004); and total stent length (HR:0.98, 95% CI:0.70-9.98; p< 0.001).

Conclusions: In Europe among selected centers dedicated to CTO revascularization, retrograde approach was performed over a 5-year period in 16.5% of these patients.